AItewan BioMedical Technology Inc.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
1. DeepBT™ Detector Plus Artificial Intelligence Brain Tumor Assisted Analysis System
2. DeepBT™ Detector Artificial Intelligence Brain Tumor Assisted Detection System
3. Medical Imaging AI Software Development
4. AI Detection Product Development
5. Medical Device Regulatory Affairs and Certification Services
2. DeepBT™ Detector Artificial Intelligence Brain Tumor Assisted Detection System
3. Medical Imaging AI Software Development
4. AI Detection Product Development
5. Medical Device Regulatory Affairs and Certification Services
The content above was translated by Ai
Founded Year
2023
Unified Business No.
89114049
Status
Active
Number of Employees
0
Total Paid-in
Capital
10,441,480 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AItewan BioMedical Technology Inc. is an AI smart medical startup spin-off approved and established under the spin-off startup regulations of National Yang Ming Chiao Tung University (NYCU). It was co-founded by Distinguished Professor Yu-Te Wu and Dr. Wan-Yuo Guo, and was born out of two phases of the National Science and Technology Council (NSTC) research commercialization programs executed by Distinguished Professor Yu-Te Wu: "AI-assisted Automatic Segmentation of Tumors in Pre- and Post-operative Multi-timepoint Brain Magnetic Resonance Images" and "DeepBT Brain Tumor Intelligent Precision Medicine System: Lesion Detection and Annotation Along the Timeline (Tracker)." The brain tumor auxiliary detection system, DeepBT Detector™, developed from the outcomes of the NSTC research commercialization programs, has signed exclusive technology licensing agreements with National Yang Ming Chiao Tung University and Taipei Veterans General Hospital. DeepBT Detector has been recognized with multiple professional awards, including the "2022 Future Tech Award," the "19th National Innovation Award - Academic Research Innovation Award," and the "National Innovation Advancement Award."
The Company will continue to cooperate with medical institutions such as National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Taichung Veterans General Hospital, Cheng Hsin General Hospital, Shin Kong Hospital, and National Yang Ming Chiao Tung University Hospital, and form strategic alliances with multiple information system vendors to promote and implement AI technology. We are committed to utilizing artificial intelligence technology to improve medical quality, reduce the burden on physicians, and provide patients with rapid, objective, quantitative, and accurate healthcare services. The company actively promotes the clinical implementation and international expansion of AI medical technology, aiming to become a leading provider of smart medical solutions in Asia.
The Company will continue to cooperate with medical institutions such as National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Taichung Veterans General Hospital, Cheng Hsin General Hospital, Shin Kong Hospital, and National Yang Ming Chiao Tung University Hospital, and form strategic alliances with multiple information system vendors to promote and implement AI technology. We are committed to utilizing artificial intelligence technology to improve medical quality, reduce the burden on physicians, and provide patients with rapid, objective, quantitative, and accurate healthcare services. The company actively promotes the clinical implementation and international expansion of AI medical technology, aiming to become a leading provider of smart medical solutions in Asia.
The content above was translated by Ai
